Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSDQ)
OTHER OTC:CLSDQ
CLSDQ Stock Chart & Stats
$0.82
<$0.01(0.46%)
At close: 4:00 PM EST
$0.82
<$0.01(0.46%)
Day’s Range― - ―
52-Week Range$0.31 - $16.35
Previous CloseN/A
VolumeN/A
Average Volume (3M)64.39K
Market Cap
$5.10M
Enterprise Value-$2.43M
Total Cash (Recent Filing)$6.80M
Total Debt (Recent Filing)$446.00K
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Mar 05, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.10
Shares Outstanding5,233,981
10 Day Avg. Volume36,098
30 Day Avg. Volume64,393
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-1.80
Price to Sales (P/S)42.14
P/FCF Ratio-2.73
Enterprise Value/Market Cap-0.48
Enterprise Value/Revenue-0.73
Enterprise Value/Gross Profit-0.85
Enterprise Value/Ebitda0.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Bears Say
Funding And Cash RunwayAnalysts warn that difficulties securing funding or partnerships and a reduced cash position increase the likelihood that the company will need external financing, potentially diluting shareholders or delaying programs.
Management And WorkforceAnalysts view the transition of all employees and senior executives into consultant roles as a sign of weakened operational capacity and heightened execution risk.
Strategic Alternatives And Asset UncertaintyAnalysts interpret the hiring of an investment bank to explore strategic alternatives and consideration of asset sales or licensing as increased strategic uncertainty that could lead to divestiture of core assets or unfavorable transaction terms.
Clearside Biomedical News
CLSDQ FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.31 and its highest was $16.35 in the past 12 months.
What is Clearside Biomedical’s market cap?
Clearside Biomedical’s market cap is $5.10M.
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is Mar 05, 2026 which is in 18 days.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on Nov 18, 2025. The company reported -$17.1 earnings per share for the quarter, missing the consensus estimate of -$0.618 by -$16.482.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Overvalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate is -0.6.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 5,233,981 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$17.1 in its last earnings report, missing expectations of -$0.618. Following the earnings report the stock price went down -8.084%.
Which hedge fund is a major shareholder of Clearside Biomedical?
Currently, no hedge funds are holding shares in CLSDQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Aptevo Therapeutics
―
Processa Pharmaceuticals
―
Rallybio
―
Cingulate Inc
―
Ownership Overview
3.37%
Insiders
3.83% Mutual Funds
0.72% Other Institutional Investors
92.08% Public Companies and
Individual Investors